Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).

Trial Details

NCT ID
NCT06163820
Phase
PHASE1 / PHASE2
Sponsor
Melanoma and Skin Cancer Trials Limited
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Bevacizumab
  • Ipilimumab
  • Nivolumab
  • Hypofractionated stereotactic radiotherapy
Locations (sample)
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • 1\. Histologically (or cytologically) proven metastatic melanoma, with radiologically confirmed brain metastases.
  • 2\. Symptomatic from brain metastases at the time of study enrolment, or brain metastases that requires corticosteroids for the management of neuro…
  • 3\. Intracranial lesions amenable to hypofractionated stereotactic radiotherapy. These are defined as all intracranial melanoma lesions greater or …
  • 4\. World Health Organisation (WHO) performance status of 0 - 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →